Search results
Showing 1851 to 1900 of 2008 results for news
New Alzheimer's treatment donanemab does not currently demonstrate value for the NHS says NICE
More evidence is needed on the clinical and cost-effectiveness of donanemab, a new treatment for mild Alzheimer’s disease.
Consultation on NHS England proposals for a phased launch of obesity injection
Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins.
Today (1 October 2024) NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of advanced breast cancer.
NICE Board says new method allowing greater weight to be given to severe diseases is working
At today's meeting (25th September 2024) our board has concluded that the new severity modifier is working as intended.
Adults with Von Hippel-Lindau disease to benefit from new treatment
NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people.
Thousands could benefit from new option for treating symptoms of uterine fibroids
As many as 30,000 adults could benefit from a new treatment for moderate to severe symptoms of uterine fibroids after we published final guidance today (14 August 2024) recommending linzagolix.
New study shows NICE Advice support can reduce appraisal timelines by 3 months
Companies who receive scientific advice from our NICE Advice service may experience a faster path to guidance publication, a study has found.
Our updated guideline to improve the diagnosis of endometriosis
The guideline makes new recommendations and updates existing ones on diagnosing and managing a condition that affects approximately 1.5 million women of reproductive age in the UK.
Updated menopause guidance includes discussion aid to support conversations about HRT
Our updated guideline on menopause emphasises the importance of an individualised approach and shared decision-making when making choices about treatment for symptoms.
More people are benefitting from NICE-recommended statins to reduce heart attacks and strokes
Around 5.3 million people in England were given a NICE-recommended statin or ezetimibe by their GP to help reduce their cholesterol during 2023/24, the largest number on record and almost 900,000 more than in 2022/23.
For the first time, the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) have collaborated to develop a UK-wide asthma guideline.
Keep the size of your waist to less than half of your height, NICE recommends
People are being encouraged to keep their waist measurement to less than half their height to reduce the risk of potential health problems.
People who have had a stroke should be offered additional rehabilitation
People who have had a stroke and who have continuing impairment or limitations on their activities should be offered additional rehabilitation to help them recover
Testing could help prevent further strokes in people with gene variant
People who have had an ischaemic stroke or transient ischaemic attack should have a genetic test to find out whether they can be treated with a drug which reduces the risk of further strokes
£1.8m funding awarded to explore guidance on regulating digital mental health tools
NICE and the MHRA have been awarded £1.8m funding by Wellcome over three years to explore and produce guidance on regulating digital mental health tools.
NICE’s latest quality standard published today (16 March 2022) helps improve the diagnosis, assessment, and prevention of fetal alcohol spectrum disorder (FASD).
Nine treatment options to be made available for adults with depression or an anxiety disorder
Six digitally enabled therapies for adults with anxiety disorders and three for adults with depression have been recommended for use in the NHS.
We've updated our health inequalities web resource so that it maps NICE guidance to frameworks for children and young people.
An early introduction to NICE’s ongoing activity in virtual wards
How 'surrogate outcomes' influence long-term health outcomes
NICE working with international organisations to develop guidance.
Statins a choice for more people to reduce risk of heart attacks and strokes
New evidence on the safety of statins means more people could benefit from them, new NICE draft guidance says.
NICE launches second consultation on genetic testing to guide treatment after a stroke
People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes.
HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases. He also highlights why effective routing is essential to getting the best care to patients across the NHS.
Thousands of people could benefit from a new oral hormone therapy for advanced hormone sensitive prostate cancer.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.
NICE launches refreshed support service for life sciences industry
NICE has launched its refreshed support service for the life sciences sector, NICE Advice.
Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment
Today, for the first time, we have given the green light to a targeted treatment for the most common form of bladder cancer.
Updated pneumonia guidelines for babies and children with mild pneumonia
Babies and children between the ages of three months and 11-years-old with pneumonia should be offered a three-day rather than five-day course of antibiotics, according to a new draft NICE guideline.
Non-invasive weight loss procedure can be an option to treat obesity
A procedure which reduces the size of the stomach by two-thirds to help people living with obesity to lose weight has been deemed safe and effective to be used in the NHS, NICE has said.
To mark Time to Talk Day (February 2) we spoke with Catherine Ruane, who acted as a carer for her father and sister, who both lived with depression.
NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.
How NICE is ensuring its topic prioritisation decisions are grounded in lived experience
Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.
NICE collaboration on streamlined licensing and patient access process for new medicines
Companies can now submit medicines for the new Innovative Licensing and Access Pathway (ILAP) following close collaboration between the NICE, drug regulators, the NHS and equivalent organisations in Scotland.
Pembrolizumab plus chemotherapy not recommend for triple negative breast cancer
Draft guidance published today (8 March 2022) by NICE does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer
How NICE manages the potential conflicts of interests of patient experts
People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.
NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where more research is needed.
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
NICE's flexibility in evaluation of new health tech and fairer patient access
Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board.
Celebrating the people who support NICE: International Volunteer Day
Applauding the members of the public who donate their valuable experience and insight to NICE.
NICE leads the way to develop a new approach to routinely value and pay for crucial antimicrobials
James Love-Koh talks about the next steps for the 3-year project to develop a routine framework for evaluating and paying for new antimicrobials.
Towards a new partnership – NICE and the voluntary and community sector
Victoria Thomas gives details of NICE’s new voluntary and community sector forum.
People in England could benefit from new endometrial cancer treatment
Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use within the Cancer Drugs Fund.
Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.
NICE recommends 'game changing' histology independent cancer drug
Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).
People with a rare blood disorder have access to a new treatment following draft guidance from NICE.
NICE recommends innovative treatment for severe blood disorder for NHS use
Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.
More than 1,000 people each year will benefit from NICE's recommendation.
People at risk of severe COVID-19 to have access to antiviral Paxlovid
A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive.
A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent womb cancer in final draft NICE guidance published today.
NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.